Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)
These updated results provide further evidence of sustained antitumor activity of T-DXd with a consistent safety profile in heavily pretreated patients with HER2-positive mBC.
PDF的下载单位、IP信息已删除
(2025-6-4)
无极微光
大力的灵雁
Zzz
老福贵儿
dew
Moonpie
昏睡的蟠桃
缓慢怜菡
pluto
阿瑟
小太阳在营业
微尘
hgy
畔畔
单纯的富
Dawang
xiaolizi
Zac
tuanheqi
MchemG
皖公网安备34019202002308